This article was originally published in The Gray Sheet
Sporicidin agrees in proposed settlement with the Federal Trade Commission to be "prohibited from making any representation about the effectiveness" of Sporicidin and other disinfectants "unless it possesses competent and reliable scientific evidence to substantiate such representations," according to the FTC. The settlement is subject to approval of the U.S. District Court in Baltimore, Maryland. Sporicidin's germicide products were seized in December 1991 in a joint FTC/FDA/EPA action. The company settled with FDA in May 1992 ("The Gray Sheet" May 18, In Brief); settlement with the EPA is still pending.
You may also be interested in...
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.